Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|April 15, 2021

Keep Therapy Approval and Delivery on Track with Avantor®

Author(s)Avantor, Inc.

From single-use assemblies that streamline mAbs production to buffer components for vaccines, innovation-advancing solutions yield treatments faster. Avantor offers the high-quality solutions, workflow expertise, and regulatory support to help you accelerate transformative breakthroughs that save lives.

Explore solutions.

Avantor, Inc.
Tel. 1.855.282.6967
afh.marketing@avantorsciences.com
www.avantorsciences.com


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.